Literature DB >> 26658970

Long-term Safety and Efficacy of Mexiletine for Patients With Skeletal Muscle Channelopathies.

Karen Joan Suetterlin1, Enrico Bugiardini1, Juan P Kaski2, Jasper M Morrow1, Emma Matthews1, Michael G Hanna1, Doreen Fialho1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26658970     DOI： 10.1001/jamaneurol.2015.2338

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN： 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  13 in total

1.  Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials.

Authors:  Bas C Stunnenberg; Joost Raaphorst; Hans M Groenewoud; Jeffrey M Statland; Robert C Griggs; Willem Woertman; Dick F Stegeman; Janneke Timmermans; Jaya Trivedi; Emma Matthews; Christiaan G J Saris; Bas J Schouwenberg; Gea Drost; Baziel G M van Engelen; Gert Jan van der Wilt
Journal:  JAMA       Date:  2018-12-11       Impact factor: 56.272

Review 2.  Guidelines on clinical presentation and management of nondystrophic myotonias.

Authors:  Bas C Stunnenberg; Samantha LoRusso; W David Arnold; Richard J Barohn; Stephen C Cannon; Bertrand Fontaine; Robert C Griggs; Michael G Hanna; Emma Matthews; Giovanni Meola; Valeria A Sansone; Jaya R Trivedi; Baziel G M van Engelen; Savine Vicart; Jeffrey M Statland
Journal:  Muscle Nerve       Date:  2020-05-27       Impact factor: 3.217

3.  Bioisosteric Modification of To042: Synthesis and Evaluation of Promising Use-Dependent Inhibitors of Voltage-Gated Sodium Channels.

Authors:  Gualtiero Milani; Maria Maddalena Cavalluzzi; Concetta Altamura; Antonella Santoro; Mariagrazia Perrone; Marilena Muraglia; Nicola Antonio Colabufo; Filomena Corbo; Elisabetta Casalino; Carlo Franchini; Isabella Pisano; Jean-François Desaphy; Antonio Carrieri; Alessia Carocci; Giovanni Lentini
Journal:  ChemMedChem       Date:  2021-10-05       Impact factor: 3.540

4.  Long-term Safety and Efficacy of Mexiletine in Myotonic Dystrophy Types 1 and 2.

Authors:  Christina Mousele; Emma Matthews; Robert D S Pitceathly; Michael G Hanna; Susan MacDonald; Konstantinos Savvatis; Aisling Carr; Christopher Turner
Journal:  Neurol Clin Pract       Date:  2021-10

5.  Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine.

Authors:  Jean-François Desaphy; Concetta Altamura; Savine Vicart; Bertrand Fontaine
Journal:  J Neuromuscul Dis       Date:  2021

6.  Multidisciplinary study of a new ClC-1 mutation causing myotonia congenita: a paradigm to understand and treat ion channelopathies.

Authors:  Paola Imbrici; Concetta Altamura; Giulia Maria Camerino; Giuseppe Felice Mangiatordi; Elena Conte; Lorenzo Maggi; Raffaella Brugnoni; Kejla Musaraj; Roberta Caloiero; Domenico Alberga; Renè Massimiliano Marsano; Giulia Ricci; Gabriele Siciliano; Orazio Nicolotti; Marina Mora; Pia Bernasconi; Jean-Francois Desaphy; Renato Mantegazza; Diana Conte Camerino
Journal:  FASEB J       Date:  2016-06-20       Impact factor: 5.191

7.  Toward precision medicine in myotonic syndromes.

Authors:  Michela De Bellis; Diana Conte Camerino; Jean-François Desaphy
Journal:  Oncotarget       Date:  2017-02-28

Review 8.  Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery.

Authors:  Paola Imbrici; Antonella Liantonio; Giulia M Camerino; Michela De Bellis; Claudia Camerino; Antonietta Mele; Arcangela Giustino; Sabata Pierno; Annamaria De Luca; Domenico Tricarico; Jean-Francois Desaphy; Diana Conte
Journal:  Front Pharmacol       Date:  2016-05-10       Impact factor: 5.810

9.  Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity.

Authors:  Michela De Bellis; Roberta Carbonara; Julien Roussel; Alessandro Farinato; Ada Massari; Sabata Pierno; Marilena Muraglia; Filomena Corbo; Carlo Franchini; Maria Rosaria Carratù; Annamaria De Luca; Diana Conte Camerino; Jean-François Desaphy
Journal:  Neuropharmacology       Date:  2016-10-13       Impact factor: 5.250

10.  Dual Action of Mexiletine and Its Pyrroline Derivatives as Skeletal Muscle Sodium Channel Blockers and Anti-oxidant Compounds: Toward Novel Therapeutic Potential.

Authors:  Michela De Bellis; Francesca Sanarica; Alessia Carocci; Giovanni Lentini; Sabata Pierno; Jean-François Rolland; Diana Conte Camerino; Annamaria De Luca
Journal:  Front Pharmacol       Date:  2018-01-12       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.